Search Result

Results for "

Vancomycin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (3) Antibiotic (24) Apoptosis (3) Autophagy (8) Bacterial (41) DNA/RNA Synthesis (1) Endogenous Metabolite (3) Isotope-Labeled Compounds (1) Parasite (1)
By Research Areas:	Cancer (8) Infection (39) Inflammation/Immunology (15) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0671

*Vancomycin* Maximum Cited Publications 54 Publications Verification	Bacterial Autophagy Antibiotic	Infection Cancer
Vancomycin is an antibiotic for the treatment of bacterial infections.

HY-17362

Vancomycin hydrochloride Maximum Cited Publications 54 Publications Verification	Bacterial Autophagy Antibiotic	Infection Cancer
Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.

HY-105282

Eremomycin MM 45289; A 82846A	Antibiotic Bacterial	Infection
Eremomycin (MM 45289) is a potent glycopeptide antibiotic closely related to Vancomycin (HY-B0671). Eremomycin shows antibacterial activity in Staphylococcus spp. and Bacillus subtilis ATCC6633, with the MIC values of 0.03-1.6 μg/mL .

HY-B0671R

Vancomycin (Standard)	Bacterial Autophagy Antibiotic	Infection Cancer
Vancomycin (Standard) is the analytical standard of Vancomycin. This product is intended for research and analytical applications. Vancomycin is an antibiotic for the treatment of bacterial infections.

HY-17362R

Vancomycin hydrochloride (Standard)	Bacterial Autophagy Antibiotic	Infection Cancer
Vancomycin (hydrochloride) (Standard) is the analytical standard of Vancomycin (hydrochloride). This product is intended for research and analytical applications. Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.

HY-B0671S3

Vancomycin-d10 TFA	Isotope-Labeled Compounds Antibiotic Bacterial Autophagy	Infection
Vancomycin-d10 (TFA) is a deuterated labeled Vancomycin . Vancomycin is an antibiotic for the treatment of bacterial infections.

HY-167841

Anti-MRSA agent 19	Bacterial Antibiotic	Infection
Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors, including vancomycin, aminoglycoside/tetracycline, and oxazolidinone resistance .

HY-N10765

Salvinolone	Bacterial	Inflammation/Immunology Cancer
Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus* (VRE).* Salvinolone shows cytotoxic activity with an IC₅₀ of 47.6 μM against the HL-60 tumor cell line for 72 h .

HY-N13196

Arcopilin A	Bacterial	Infection
Arcopilin A (compound Arcopilin A(1))is an antibacterial agent. Arcopilin A has weak inhibitory effects on fungal pathogens and Gram-positive bacteria, with IC₅₀ values of 8.9 μg/mL and 14 μg/mL for cells KB-3-1 and L929, but it can effectively destroy preformed biofilms of Staphylococcus aureus. Arcopilin A can enhance the activities of gentamicin (GM; HY-K1050) and vancomycin (Vac; HY-B0671) by 115 and 31 times, respectively .

HY-161935

6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid	Bacterial	Infection Inflammation/Immunology
6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .

HY-B1924

Norvancomycin hydrochloride 1 Publications Verification Desmethyl-Vancomycin hydrochloride	Bacterial Antibiotic	Infection
Norvancomycin hydrochloride is suitable for endocarditis, osteomyelitis, pneumonia, sepsis or soft tissue infections caused by Staphylococcus aureus (including methicillin-resistant strains and multi-drug-resistant strains).

HY-106574

Ceftobiprole medocaril BAL5788	Bacterial	Infection Inflammation/Immunology
Ceftobiprole medocaril (BAL5788) is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .

HY-106574A

Ceftobiprole medocaril sodium BAL5788 sodium	Bacterial	Infection Inflammation/Immunology
Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .

HY-112579

Ceftobiprole 2 Publications Verification Ro 63-9141; BAL 9141	Bacterial Antibiotic	Infection Inflammation/Immunology
Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC₉₀ value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia .

HY-112959

Telavancin TD-6424	Antibiotic Bacterial	Infection
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .

HY-144621

Antibacterial agent 75	Bacterial	Infection Inflammation/Immunology
Antibacterial agent 75 (compound 24) is an antibacterial agent. Antibacterial agent 75 (compound 24) is able to re-sensitize VRSA to vancomycin .

HY-121000

Albocycline Ingramycin	Antibiotic Bacterial	Infection
Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .

HY-156198

Bottromycin A2	Antibiotic Bacterial	Infection
Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .

HY-P5204

Enterocin Hybrid 1 K1-EJ hybrid	Bacterial	Infection
Enterocin Hybrid 1 is a antibacterial agent, a antibacterial composition. Enterocin Hybrid 1 inhibits Vancomycin (HY-B0671)-resistant E. faecium, Staphylococcus haemoliticus .

HY-111071

Nilofabicin CG-400549	Bacterial Antibiotic	Infection Inflammation/Immunology
Nilofabicin is an enoyl-(acyl-carrier protein) reductase (FabI) inhibitor. Nilofabicin had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin .

HY-164123

Antibiofilm agent-9	Bacterial	Infection
Antibiofilm agent-9 (Compound 4) is a pyrrolomycin derivative with antibacterial activity. Antibiofilm agent-9 inhibits Bacillus anthracis with MIC of 0.031 μg/mL. Antibiofilm agent-9 exhibits antibiofilm activity with 84% biofilm inhibition (24 h, 8.0 μg/mL). Antibiofilm agent-9 exhibits a good pharmacokinetic characters in mouse model .

HY-169105

DNA Gyrase-IN-12	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-12 (Compound 6d) is a DNA gyrase inhibitor. DNA Gyrase-IN-12 has Antibacterial activity and MIC value of vancomycin-intermediate S. aureus (VISA) and Enterococcus faecalis strains is between 0.031 and 0.0625 μg/mL .

HY-162782A

V–C6–Bg-PhCl TFA	Antibiotic Bacterial	Infection
V–C6–Bg-PhCl TFA (compound 5e) is a biguanide-vancomycin conjugate. V–C6–Bg-PhCl TFA has broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria .

HY-163399

Antibacterial agent 197	Bacterial	Infection
Antibacterial agent 197 (compound 1-deAA) is a termination inhibitor of non-classical anhydroglycosyl receptors and anhydrowall peptide-type peptidoglycan (PG) in bacterial TGase, with activity against Staphylococcus aureus. Antibacterial agent 197 synergizes with Vancomycin (HY-B0671) and is its antibacterial adjuvant .

HY-117845

Citreamicin alpha LL-E19085α	Others	Infection
Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.

HY-P3361

IDR-1018	Parasite Bacterial Antibiotic	Infection Inflammation/Immunology
IDR-1018 is an innate defense regulator conjugate, with MICs of 16 μg/mL for MRSA USA300 LAC, MRSA SAP 0017 and S. epidermidis ATCC14990. IDR-1018 can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate) .

HY-P3078

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

HY-14849

PTZ601 Razupenem; SM 216601; SMP 601	Antibiotic Bacterial	Others
PTZ601 (SMP 601) is an antibiotic, which inhibits the gram-positive bacteria, including the Vancomycin (HY-B0671)-resistant Enterococcus faecium (VREF) and Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). PTZ601 exhibits antimicrobial activity in infected mouse models .

HY-161263

Antibacterial agent 182	Bacterial	Infection
Antibacterial agent 182 (compound 8c) is an antibacterial agent that shows antibacterial activity against various Gram-positive bacteria, particularly against Vancomycin-resistant Enterococcus faecalis (MIC ≤0.125 μg/mL). Antibacterial agent 182 inhibits biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa at sub-MIC doses .

HY-143326

Antibacterial agent 83	Bacterial	Infection
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .

HY-16485

Telavancin hydrochloride TD-6424 hydrochloride	Antibiotic Bacterial	Infection
Telavancin hydrochloride is the hydrochloride form of Telavancin (HY-112959). Telavancin hydrochloride is a semisynthetic derivative of vancomycin, and exhibits antibacterial efficacy through inhibition of cell wall synthesis and disruption of cell membrane barrier function. Telavancin hydrochloride is efficient against antibiotic resistant S. aureus strains MRSA, VISA, and hVISA. Telavancin hydrochloride attenuates gram positive bacteria induced complicated skin and skin structure infections (cSSSI) .

HY-133119

PK150	Bacterial	Infection
PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively .

HY-A0279

Pristinamycin Pristinamycine	Bacterial Antibiotic	Infection
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .

HY-N0148A

Rutin hydrate 10+ Cited Publications Rutoside hydrate; Quercetin 3-O-rutinoside hydrate	Amyloid-β Autophagy Apoptosis Endogenous Metabolite	Neurological Disease Cancer
Rutin (Rutoside) hydrate is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin hydrate can cross the blood brain barrier. Rutin hydrate attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .

HY-117254

BAS00127538	Bacterial	Infection
BAS00127538 is a Lipid II inhibitor with antibacterial activity. As the first small molecule Lipid II inhibitor, BAS00127538 has a structure that is significantly different from compounds that naturally bind to Lipid II, such as vancomycin. The activity of BAS00127538 in terms of cytotoxicity and Lipid II binding is of great significance in antibacterial effects. Studies on BAS00127538 have shown that it has the potential to inhibit infection .

HY-146811

HSGN-94	Bacterial	Inflammation/Immunology
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .

HY-N0148

Rutin 10+ Cited Publications Rutoside; Quercetin 3-O-rutinoside	Amyloid-β Autophagy Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-162775

TST1N-224	Bacterial Antibiotic	Infection
TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC₅₀=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (K_D=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974) .

HY-N0148R

Rutin (Standard)	Amyloid-β Autophagy Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Rutin (Standard) is the analytical standard of Rutin. This product is intended for research and analytical applications. Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .

HY-B1831

Oritavancin LY 333328; Orbactiv	Antibiotic Bacterial	Infection Inflammation/Immunology
Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .

HY-116863

KKL-40	Bacterial	Infection
KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .

HY-125745

Loloatin B 10	Antibiotic Bacterial	Infection
Loloatin B 10 is an antibiotic, which exhibits antibacterial efficacy against gram positive antibiotic resistant human pathogens .

HY-B1831A

Oritavancin diphosphate 1 Publications Verification LY333328 diphosphate	Bacterial Antibiotic	Infection Inflammation/Immunology
Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .

HY-B1831AR

Oritavancin diphosphate (Standard)	Bacterial Antibiotic	Infection Inflammation/Immunology
Oritavancin (diphosphate) (Standard) is the analytical standard of Oritavancin (diphosphate). Oritavancin diphosphate (Standard), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate (Standard) shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate (Standard) inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate (Standard) inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate (Standard) enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .

Cat. No.	Product Name

HY-L110

Cyclic Peptide Library

91 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 91 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type

HY-69174

1-Amino-2,5-anhydro-1-deoxy-D-mannitol

Microbial Culture

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

Cat. No.	Product Name	Target	Research Area